Updated

Real-world data on Novo Nordisk's Wegovy pill form indicates that patients continuing the once-daily oral formulation maintained weight-loss results previously achieved via weekly GLP-1 injections, suggesting a viable switch path for patients seeking more convenient dosing. The finding supports the commercial viability of oral obesity medications as an alternative to injectable therapeutics. The result expands the potential market for Novo's obesity treatment franchise by demonstrating that oral formulation does not compromise efficacy, potentially capturing patients who prefer pill-based therapy over injection regimens.